Lung Cancer Research Foundation
3-29-19
Click to read more about each approval:
http://www.lungcancerresearchfoundation.org/lung-cancer/recently-approved-lung-cancer-treatments
MARCH 2019
FDA approved atezolizamab (Tecentriq) in combination with chemotherapy for first line treatment of extensive stage SCLC.
DECEMBER 2018
FDA approved atezolizumab (Tecentriq) in combination with chemotherapy as a first line treatment of non-squamous non-small cell lung cancer (NSCLC) that has metastasized.
NOVEMBER 2018
FDA approved lorlatinib (Lorbrena) as a second or third line treatment for patients with ALK+ metastatic non-small cell lung cancer (NSCLC).
OCTOBER 2018
FDA approved pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).
SEPTEMBER 2018
FDA approved dacomitinib (Vizimpro) as a first-line treatment for patients with EFGR+ metastatic non-small cell lung cancer (NSCLC).
AUGUST 2018
FDA approved pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
FDA approved nivolumab (Opdivo) as a third-line treatment for patients with metastatic small cell lung cancer (SCLC).
APRIL 2018
FDA approved osimertinib (Tagrisso) as a first-line treatment for EGFR+ patients with metastatic non-small cell lung cancer (NSCLC).
FEBRUARY 2018
FDA approved durvalumab (Imfinzi) after chemoradiation treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC).
JANUARY 2018
FDA approved afatinib (Gilotrif) for a broadened indication in first-line treatment of EGFR+ patients with metastatic non-small cell lung cancer (NSCLC).
3-29-19
Click to read more about each approval:
http://www.lungcancerresearchfoundation.org/lung-cancer/recently-approved-lung-cancer-treatments
MARCH 2019
FDA approved atezolizamab (Tecentriq) in combination with chemotherapy for first line treatment of extensive stage SCLC.
DECEMBER 2018
FDA approved atezolizumab (Tecentriq) in combination with chemotherapy as a first line treatment of non-squamous non-small cell lung cancer (NSCLC) that has metastasized.
NOVEMBER 2018
FDA approved lorlatinib (Lorbrena) as a second or third line treatment for patients with ALK+ metastatic non-small cell lung cancer (NSCLC).
OCTOBER 2018
FDA approved pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).
SEPTEMBER 2018
FDA approved dacomitinib (Vizimpro) as a first-line treatment for patients with EFGR+ metastatic non-small cell lung cancer (NSCLC).
AUGUST 2018
FDA approved pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
FDA approved nivolumab (Opdivo) as a third-line treatment for patients with metastatic small cell lung cancer (SCLC).
APRIL 2018
FDA approved osimertinib (Tagrisso) as a first-line treatment for EGFR+ patients with metastatic non-small cell lung cancer (NSCLC).
FEBRUARY 2018
FDA approved durvalumab (Imfinzi) after chemoradiation treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC).
JANUARY 2018
FDA approved afatinib (Gilotrif) for a broadened indication in first-line treatment of EGFR+ patients with metastatic non-small cell lung cancer (NSCLC).